Visit our Clinical Hub ยป

Direct Healthcare Professional Communication

12 April 2019
print version

Systemic and inhaled quinolone and fluoroquinolone antibiotics - risk of disabling, long lasting and potential irreversible side effects and restrictions on use.

Please see attached letter for more information . 

Documents

 Direct Healthcare Professional Communication 09.04.2019 (Direct_Healthcare_Professional_Communication_09.04.2019.pdf | 1.19 MB)

 

Email: library@icgp.ie, Tel: 01 6763705, Fax: 01 6765850